

Philippines HIV Country Profile 2022

WHO/UCN/HHS/21.10

Philippines





Health sector cascade (2021)

Indicator

Value

Percent of 95-95-95

People living with HIV who know their status

88 964

People living with HIV receiving ART

56 385


41%

(2021)

2.7

Estimated % of pregnant women living with HIV who received ARVs for PMTCT (2021)

Estimated ART coverage children and adults (2021)



Trend since 2010 (328%


Reported number of children receiving ART

Reported number of people living with HIV receiving ART

Reported number of people living with HIV receiving ART (adults 15+)

Epidemiological HIV data (2021)	Value
Estimated number of women (15+) living with HIV	9 400
Estimated number of people newly infected with HIV	21 000
Estimated number of people living with HIV	140 000
Estimated number of people dying from HIV-related causes	1 200
Estimated number of children aged 0 to 14 living with HIV	750
Estimated incidence rate per 1000 uninfected population	0.19
Estimated adult (15-49) prevalence	0.2%

Estimated incidence rate per 1000 uninfected population	0.19
Estimated adult (15-49) prevalence	0.2%
A .:	
Antiretroviral therapy (ART) (2021)	
Estimated ART coverage	41%
Latinated Aixi Coverage	4170
Estimated ART coverage (adults 15+)	41%
Estimated ART coverage (children, 0-14) ¹	19%



2012 2013 2014 2015 2016

2017

Value

Year

Year

Trend since 2010 (401%)

■ Lower bound ◆ Point estimate ■ Upper bound

Elimination of mother-to-child transmission (EMTCT) of HIV &

syphilis		
Reported number of pregnant women living with HIV who received antiretrovirals for PMTCT	81	2021
Final transmission rate including breastfeeding period ³ (%)	38.6%	2021
Estimated percentage of pregnant women living with HIV who received antiretrovirals for PMTCT ² (%)	15%	2021
Antenatal care coverage - at least one visit (%)	93.8%	2017
Antenatal care coverage - at least four visits (%)	86.5%	2017
Antenatal care attendees who were tested for syphilis (%)	N/A	N/A
Antenatal care attendees who tested positive for syphilis and who received benzathine penicillin IM (%)	43.33%	2011
Antenatal care attendees who tested positive for syphilis (%)	1.41%	2019
% of pregnant women with known HIV status	<1%	2021
% of infants born to women living with HIV receiving a virological test within two months of birth (EID) ¹ (%)	7.1%	2021

(green, orange, red) is used to indicate if the country is on target to meet 2020 targets: 190% 295% 3Less than 5


Key populations (2021)

Tracing indicators for elimination of mother-to-child transmission. A color scheme

5.0% HIV prevalence among men who have sex with men (%) HIV prevalence among people who inject drugs (%) N/A HIV prevalence among sex workers (%) N/A Needles distributed per person who inject drugs per year N/A Percentage condom use among sex workers with most recent client 85.3% Percentage of people who inject drugs receiving OST N/A Median annual price of ARV drug regimens for adults First line **Second line** ◆[TDF+3TC+EFV] [600+300+300]mg ◆[TDF+3TC]+[LPV/r] ◆[TDF+FTC]+[LPV/r] ◆[ZDV+3TC]+[LPV/r]

56 385

56 241



National HIV policies and plans (2022)			
Indicator	Value Value		
Implementation of national policy on HIV self-testing (HIVST)	No HIVST policy but policy in development		
Treatment initiation threshold among adults and adolescents	Treat all regardless of CD4 count		
Implementation of treat all policy among adults and adolescents	Implemented countrywide (>95% of treatment sites)		
Implementation of lifelong ART for pregnant & breastfeeding women	Implemented		
Treatment initiation threshold among children	Treat all, regardless of age		
Adoption of WHO 2017 recommendation on rapid initiation of ART	Rapid initiation within 7 days of HIV diagnosis		
National policy supporting community delivery of ART	Policy implemented nationally		
Adoption of WHO recommendation to offer package of interventions for patients with advanced HIV disease	Not adopted		
Policy on the frequency of clinic visits for adults who are doing well on antiretroviral therapy	data not available		
Policy on how frequently adults who are doing well on antiretroviral therapy should pick-up antiretroviral medicine (MMD)	data not available		
Dolutegravir (DTG) as part of 1st line ARVs for adults and adolescents	DTG introduced in national guidelines and procurement initiated		
Implementation of national policy on viral load monitoring	Implemented countrywide (>95% of treatment sites)		
Availability of point-of-care viral load testing	Point-of-care viral load testing available in any health facility		
National M&E plan or strategy for HIV	Stand-alone HIV monitoring and evaluation strategy or plan		

WHO (2022), Population Division of the Department of Economic and Social Affairs of the United Nations Secretariat (2022), UNICEF Data (2022), United Nations Development Programme (2022), Spectrum estimates UNAIDS/WHO (2022), World Bank (2022)

Sources: Global AIDS Monitoring UNAIDS/WHO/UNICEF (2022), Global Health Expenditure Database WHO (2022), Global Health Observatory WHO (2022), Global Price Reporting Mechanism

Definition of acronyms: PLHIV = People living with HIV, HIV = Human Immunodeficiency Virus, AIDS = Acquired Immunodeficiency Syndrome, ART = Antiretroviral Therapy,

ARVs = Antiretrovirals, PMTCT = Prevention of Mother-to-Child Transmission, EID = Early Infant Diagnosis, OST = Opioid Substitution Therapy, MMD = Multi-month Dispensing